Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTPOYU7)

DTT Name Transthyretin messenger RNA (TTR mRNA)
Synonyms Transthyretin (mRNA); TBPA (mRNA); Prealbumin (mRNA); PALB (mRNA); ATTR (mRNA)
Gene Name TTR
DTT Type
Successful target
 [1]
BioChemical Class
mRNA target
UniProt ID
TTHY_HUMAN
TTD ID
T23389
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDT
WEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDS
GPRRYTIAALLSPYSYSTTAVVTNPKE
Function Probably transports thyroxine from the bloodstream to the brain. Thyroid hormone-binding protein.
KEGG Pathway
Thyroid hormone synthesis (hsa04918 )
Reactome Pathway
The canonical retinoid cycle in rods (twilight vision) (R-HSA-2453902 )
Non-integrin membrane-ECM interactions (R-HSA-3000171 )
Retinoid metabolism and transport (R-HSA-975634 )
Amyloid formation (R-HSA-977225 )
Retinoid cycle disease events (R-HSA-2453864 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplontersen DMON9CY Amyloid polyneuropathy 5D00.20 Approved [2]
Patisiran DMWSA0V Amyloidosis 5D00 Approved [1]
Vutrisiran DMM1Z9G Hereditary amyloidosis 5D00.2 Approved [3]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS-TTR DM4U5NF Amyloidosis 5D00 Phase 3 [4]
Revusiran DM5E73H Amyloidosis 5D00 Phase 3 [1]
ALN-TTR01 DMCSEUY Amyloidosis 5D00 Phase 1 [5]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217388
3 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals.
4 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
5 Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.